10.11.2014 13:44:18
|
Dendreon Q3 Loss Narrows - Quick Facts
(RTTNews) - Dendreon Corp. (DNDN), a biotechnology firm focused on cancer treatments, reported third-quarter net loss of $22.1 million or $0.14 per share, narrower than $67.2 million or $0.44 per share in the comparable quarter last year.
On average, 13 analysts polled by Thomson Reuters expected the company to report a loss of $0.20 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue increased to $73.12 million from $68.00 million a year earlier, while 11 analysts estimated revenues of $75.27 million for the quarter.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Dendreon Corp.mehr Nachrichten
Keine Nachrichten verfügbar. |